Alopecia areata (AA) is a common, chronic, non-scarring autoimmune disorder of the hair follicle. The disease can affect any hair-bearing region of the body, though the scalp is by far the most frequently involved site. Clinically, AA presents along a broad spectrum: involvement may be limited to one or several small, well-demarcated patches, or it may extend to complete loss of all scalp hair, a subtype designated alopecia totalis (AT), or complete loss of all scalp and body hair, known as alopecia universalis (AU). JAK inhibitors are transforming the treatment landscape for severe AA considerably: baricitinib, ritlecitinib, and deuruxolitinib are FDA-approved, while baricitinib and ritlecitinib are EMA-approved in the EU.

Oral JAK inhibitors have moved severe alopecia areata from watchful waiting to active treatment, but our latest KOL interviews make clear the bar for the next entrant has moved with them. Our Thought Leadership report, Alopecia Areata: KOL Expectations of an Emerging Therapy (July 2026), distills conversations with the US, UK and German dermatologists into five expectations any new therapy will be measured against:

• Depth of regrowth: the bar has moved from SALT<20 toward complete regrowth
• Durability off treatment: relapse on withdrawal is the #1 limitation KOLs cite
• Safety and monitoring: appetite for a cleaner, non-JAK profile even without superiority
• Access and reimbursement: the binding constraint, not efficacy
• Breadth and selection: pediatric labels, non-scalp endpoints, and biomarkers as open white space

Each comes with a direct implication for developers and commercial teams.